Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
Quantum BioPharma (NASDAQ: QNTM) has announced its participation in two upcoming investor conferences in May 2025. The company's Head of Finance and M&A, Jason Sawyer, will attend the Sidoti Micro-Cap Conference on May 21 and the A.G.P. Virtual Healthcare Conference on May 22.
At the Sidoti conference, Mr. Sawyer will deliver a webcast presentation from 9:15-9:45 AM ET and conduct one-on-one meetings with institutional investors. The following day at the A.G.P. conference, he will participate in virtual one-on-one meetings with investors. Interested parties can schedule meetings through conference representatives or by contacting QNTM@mzgroup.us.
Quantum BioPharma (NASDAQ: QNTM) ha annunciato la sua partecipazione a due conferenze per investitori previste per maggio 2025. Il Responsabile Finanziario e delle Fusioni e Acquisizioni, Jason Sawyer, sarà presente alla Sidoti Micro-Cap Conference il 21 maggio e alla A.G.P. Virtual Healthcare Conference il 22 maggio.
Durante la conferenza Sidoti, il Sig. Sawyer terrà una presentazione in webcast dalle 9:15 alle 9:45 ET e avrà incontri individuali con investitori istituzionali. Il giorno seguente, alla conferenza A.G.P., parteciperà a incontri virtuali one-to-one con investitori. Gli interessati possono fissare appuntamenti tramite i rappresentanti delle conferenze o contattando QNTM@mzgroup.us.
Quantum BioPharma (NASDAQ: QNTM) ha anunciado su participación en dos próximas conferencias para inversores en mayo de 2025. El Jefe de Finanzas y Fusiones y Adquisiciones de la empresa, Jason Sawyer, asistirá a la Sidoti Micro-Cap Conference el 21 de mayo y a la A.G.P. Virtual Healthcare Conference el 22 de mayo.
En la conferencia Sidoti, el Sr. Sawyer realizará una presentación en webcast de 9:15 a 9:45 AM ET y mantendrá reuniones individuales con inversores institucionales. Al día siguiente, en la conferencia A.G.P., participará en reuniones virtuales uno a uno con inversores. Los interesados pueden programar reuniones a través de los representantes de la conferencia o contactando a QNTM@mzgroup.us.
Quantum BioPharma (NASDAQ: QNTM)는 2025년 5월에 열리는 두 개의 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 회사의 재무 및 인수합병 책임자인 Jason Sawyer가 5월 21일 Sidoti Micro-Cap Conference와 5월 22일 A.G.P. Virtual Healthcare Conference에 참석합니다.
Sidoti 컨퍼런스에서 Sawyer 씨는 오전 9시 15분부터 9시 45분(동부시간)까지 웹캐스트 발표를 진행하며 기관 투자자들과 일대일 미팅을 가질 예정입니다. 다음 날 A.G.P. 컨퍼런스에서는 투자자들과 가상 일대일 미팅에 참여합니다. 관심 있는 분들은 컨퍼런스 담당자나 QNTM@mzgroup.us로 연락하여 미팅을 예약할 수 있습니다.
Quantum BioPharma (NASDAQ : QNTM) a annoncé sa participation à deux prochaines conférences pour investisseurs en mai 2025. Le responsable des finances et des fusions-acquisitions de la société, Jason Sawyer, assistera à la Sidoti Micro-Cap Conference le 21 mai ainsi qu'à la A.G.P. Virtual Healthcare Conference le 22 mai.
Lors de la conférence Sidoti, M. Sawyer présentera un webcast de 9h15 à 9h45 (heure de l’Est) et tiendra des réunions individuelles avec des investisseurs institutionnels. Le lendemain, lors de la conférence A.G.P., il participera à des réunions virtuelles en tête-à-tête avec des investisseurs. Les personnes intéressées peuvent planifier des rendez-vous via les représentants des conférences ou en contactant QNTM@mzgroup.us.
Quantum BioPharma (NASDAQ: QNTM) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Mai 2025 angekündigt. Der Finanz- und M&A-Leiter des Unternehmens, Jason Sawyer, wird an der Sidoti Micro-Cap Conference am 21. Mai sowie an der A.G.P. Virtual Healthcare Conference am 22. Mai teilnehmen.
Auf der Sidoti-Konferenz wird Herr Sawyer von 9:15 bis 9:45 Uhr ET eine Webcast-Präsentation halten und Einzelgespräche mit institutionellen Investoren führen. Am folgenden Tag wird er auf der A.G.P.-Konferenz an virtuellen Einzelgesprächen mit Investoren teilnehmen. Interessenten können Termine über die Konferenzvertreter oder per Kontaktaufnahme unter QNTM@mzgroup.us vereinbaren.
- None.
- None.
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”) a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that management will attend the Sidoti Micro-Cap Conference and the A.G.P. Virtual Healthcare Conference in May 2025.
Quantum BioPharma Head of Finance and M&A Jason Sawyer will attend the Sidoti Micro-Cap Conference on May 21 and the A.G.P. Virtual Healthcare Conference on May 22, where Mr. Sawyer is scheduled to host one-on-one meetings with institutional investors at both events and host a webcast presentation at the Sidoti Micro-Cap Conference.
Sidoti Micro-Cap Conference
Date: Wednesday, May 21, 2025
Format: Presentation & Virtual 1x1 Meetings
Presentation: 9:15-9:45 AM ET in Track 1
Webcast: Click here
Attendee: Head of Finance and M&A Jason Sawyer
Conference Website: Click here
A.G.P. Virtual Healthcare Conference
Date: Thursday, May 22, 2025
Format: Virtual 1x1 Meetings
Attendee: Head of Finance and M&A Jason Sawyer
Conference Website: Click here
For more information on the Sidoti Micro-Cap Conference, A.G.P. Virtual Healthcare Conference, or to schedule a one-on-one meeting with Quantum BioPharma management, please contact your conference representative or you may also email your request to QNTM@mzgroup.us or call Chris Tyson at (949) 491-8235.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of
For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
QNTM@mzgroup.us
www.mzgroup.us
FAQ
When is Quantum BioPharma (QNTM) presenting at the Sidoti Micro-Cap Conference 2025?
Who will represent Quantum BioPharma at the May 2025 investor conferences?
Which investor conferences will Quantum BioPharma (QNTM) attend in May 2025?
How can investors schedule meetings with Quantum BioPharma management at these conferences?
